2020
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
Giri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SD, Ma X, Gross CP, Davidoff AJ, Neparidze N. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Advances 2020, 4: 2245-2253. PMID: 32442299, PMCID: PMC7252537, DOI: 10.1182/bloodadvances.2019001425.Peer-Reviewed Original ResearchConceptsHigh-risk chromosomal abnormalitiesOverall survivalMultiple myelomaChromosome 1 abnormalitiesCox proportional hazards regression modelHigh-risk multiple myelomaProportional hazards regression modelsFlatiron Health databaseR-ISS stageMedian overall survivalFirst-line therapyDays of diagnosisInferior overall survivalInternational Staging SystemKaplan-Meier methodSurvival of patientsWorse overall survivalLog-rank testHazards regression modelsCommon genetic aberrationsElectronic health recordsEligible patientsContemporary cohortImmunomodulatory agentsStaging system
2009
Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
Neparidze N, Dhodapkar MV. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy. Clinical Advances In Hematology And Oncology 2009, 7: 677-81, 687-90. PMID: 20040909, PMCID: PMC3612541.Peer-Reviewed Original ResearchConceptsWaldenstrom's macroglobulinemiaLymphoplasmacytic cellsClonal lymphoplasmacytic cellsHigh-dose chemotherapyBone marrow infiltrationInternational Staging SystemStem cell transplantationB-cell disordersComplete remissionFrontline therapyObjective responseMarrow infiltrationCell transplantationStaging systemTherapeutic armamentariumMonoclonal gammopathyNovel agentsMacroglobulinemiaTherapyProteasome inhibitorsDisease biologyNucleoside analoguesPromising activityRecent studiesRecent advances